{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:28:22Z","timestamp":1791635302994,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Considering the re-emergence of poliomyelitis (PM) in non-endemic regions, it becomes apparent that vaccine preventable diseases can rapidly develop epi- or even pandemic potential. Evaluation of the current vaccination status is required to inform patients, health care providers and policy makers about vaccination gaps.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between October 28 2022 and November 23 2022, 5,989 adults from the VACCELEREATE Volunteer Registry completed an electronic case report form on their previous PM vaccine doses including number, types\/-valencies and the time of administration based on their vaccination records. A uni-\/multivariable regression analysis was performed to assess associations in participant characteristics and immunization status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among German volunteers (n\u2009=\u20095,449), complete PM immunization schedule was found in 1,981 (36%) participants. Uncertain immunization, due to unknown previous PM vaccination (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009313, 6%), number of doses (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009497, 9%), types\/-valencies (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091,233, 23%) or incoherent immunization schedule (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009149, 3%) was found in 40% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092,192). Out of 1,276 (23%) participants who reported an incomplete immunization schedule, 62 (1%) never received any PM vaccine. A total of 5,074 (93%) volunteers reported having been vaccinated at least once and 2,087 (38%) indicated that they received vaccination within the last ten years. Female sex, younger age, as well as availability of first vaccination record were characteristics significantly associated with complete immunization (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Full PM immunization schedule was low and status frequently classified as uncertain due to lack of details on administered doses. There is an obviousneed for improved recording to enable long-term access to detailed vaccination history in the absence of a centralized immunization register.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-024-02296-9","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T16:36:11Z","timestamp":1716914171000},"page":"1563-1574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Challenges in assessing the immunization status of adults in Germany\u2014lessons from a population-based VACCELERATE survey on polio vaccination"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5327-2937","authenticated-orcid":false,"given":"Julia A.","family":"Nacov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9152-2469","authenticated-orcid":false,"given":"Jannik","family":"Stemler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6766-8297","authenticated-orcid":false,"given":"Jon","family":"Salmanton-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1425-7352","authenticated-orcid":false,"given":"Louise M.","family":"Cremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1873-3953","authenticated-orcid":false,"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4337-6222","authenticated-orcid":false,"given":"Patrick W. G.","family":"Mallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5893-1081","authenticated-orcid":false,"given":"Zoi Dorothea","family":"Pana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0378-5697","authenticated-orcid":false,"given":"Heinz-Josef","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the VACCELERATE Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"2296_CR1","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1016\/S2468-2667(20)30082-7","volume":"5","author":"J Bayham","year":"2020","unstructured":"Bayham J, Fenichel EP. Impact of school closures for COVID-19 on the US health-care workforce and net mortality: a modelling study. Lancet Public Health. 2020;5:e271\u20138. https:\/\/doi.org\/10.1016\/S2468-2667(20)30082-7.","journal-title":"Lancet Public Health"},{"key":"2296_CR2","doi-asserted-by":"publisher","first-page":"1604961","DOI":"10.3389\/ijph.2022.1604961","volume":"67","author":"MS Bourrier","year":"2022","unstructured":"Bourrier MS, Deml MJ. The legacy of the pandemic preparedness regime: an integrative review. Int J Public Health. 2022;67:1604961. https:\/\/doi.org\/10.3389\/ijph.2022.1604961.","journal-title":"Int J Public Health"},{"key":"2296_CR3","doi-asserted-by":"publisher","first-page":"100699","DOI":"10.1016\/j.hlpt.2022.100699","volume":"12","author":"YT Chen","year":"2023","unstructured":"Chen YT. Effect of vaccination patterns and vaccination rates on the spread and mortality of the COVID-19 pandemic. Health Policy Technol. 2023;12:100699. https:\/\/doi.org\/10.1016\/j.hlpt.2022.100699.","journal-title":"Health Policy Technol"},{"key":"2296_CR4","doi-asserted-by":"publisher","first-page":"100136","DOI":"10.1016\/j.puhip.2021.100136","volume":"2","author":"E Mbunge","year":"2021","unstructured":"Mbunge E, Dzinamarira T, Fashoto SG, Batani J. Emerging technologies and COVID-19 digital vaccination certificates and passports. Public Health Pract (Oxf). 2021;2:100136. https:\/\/doi.org\/10.1016\/j.puhip.2021.100136.","journal-title":"Public Health Pract (Oxf)"},{"key":"2296_CR5","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1080\/21645515.2019.1621147","volume":"15","author":"F Wiot","year":"2019","unstructured":"Wiot F, Shirley J, Prugnola A, Di Pasquale A, Philip R. Challenges facing vaccinators in the 21(st) century: results from a focus group qualitative study. Hum Vaccin Immunother. 2019;15:2806\u201315. https:\/\/doi.org\/10.1080\/21645515.2019.1621147.","journal-title":"Hum Vaccin Immunother"},{"key":"2296_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.25646\/10838","volume":"48","author":"T Rieck","year":"2022","unstructured":"Rieck T, Feig M, Siedler A. Impfquoten von Kinderschutzimpfungen in Deutschland \u2013aktuelle Ergebnisse aus der RKI-Impfsurveillance. Epidemiologisches Bulletin. 2022;48:3\u201325. https:\/\/doi.org\/10.25646\/10838.","journal-title":"Epidemiologisches Bulletin"},{"key":"2296_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/cpmc.47","author":"EG Viktorova","year":"2018","unstructured":"Viktorova EG, Khattar S, Samal S, Belov GA. Poliovirus Replicon RNA generation, transfection, packaging, and quantitation of replication. Curr Protoc Microbiol. 2018. https:\/\/doi.org\/10.1002\/cpmc.47.","journal-title":"Curr Protoc Microbiol"},{"key":"2296_CR8","first-page":"391","volume":"73","author":"CF Pait","year":"1950","unstructured":"Pait CF. Virology of poliomyelitis. Calif Med. 1950;73:391\u20133.","journal-title":"Calif Med"},{"key":"2296_CR9","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.15585\/mmwr.mm7034a1","volume":"70","author":"JP Bigouette","year":"2021","unstructured":"Bigouette JP, Wilkinson AL, Tallis G, Burns CC, Wassilak SGF, Vertefeuille JF. Progress toward polio eradication - worldwide, January 2019-June 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1129\u201335. https:\/\/doi.org\/10.15585\/mmwr.mm7034a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2296_CR10","volume-title":"Global eradication of poliomyelitis by the year 2000","author":"World Health A","year":"1988","unstructured":"World Health A. Global eradication of poliomyelitis by the year 2000. Geneva: World Health Organization; 1988."},{"key":"2296_CR11","first-page":"1031","volume":"63","author":"OM Kew","year":"2014","unstructured":"Kew OM, Cochi SL, Jafari HS, Wassilak SG, Mast EE, Diop OM, et al. Possible eradication of wild poliovirus type 3\u2013worldwide, 2012. MMWR Morb Mortal Wkly Rep. 2014;63:1031\u20133.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2296_CR12","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.15585\/mmwr.mm7049a1","volume":"70","author":"MM Alleman","year":"2021","unstructured":"Alleman MM, Jorba J, Henderson E, Diop OM, Shaukat S, Traor\u00e9 MA, et al. Update on vaccine-derived poliovirus outbreaks - worldwide, January 2020-June 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1691\u20139. https:\/\/doi.org\/10.15585\/mmwr.mm7049a1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2296_CR13","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1016\/j.vaccine.2017.04.036","volume":"35","author":"N Khetsuriani","year":"2017","unstructured":"Khetsuriani N, Perehinets I, Nitzan D, Popovic D, Moran T, Allahverdiyeva V, et al. Responding to a cVDPV1 outbreak in Ukraine: Implications, challenges and opportunities. Vaccine. 2017;35:4769\u201376. https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.036.","journal-title":"Vaccine"},{"key":"2296_CR14","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1097\/inf.0000000000003696","volume":"41","author":"RJ Leggiadro","year":"2022","unstructured":"Leggiadro RJ. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater\u2014New York, June-August 2022. Pediatr Infect Dis J. 2022;41:898. https:\/\/doi.org\/10.1097\/inf.0000000000003696.","journal-title":"Pediatr Infect Dis J"},{"key":"2296_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01804-9","author":"D Klapsa","year":"2022","unstructured":"Klapsa D, Wilton T, Zealand A, Bujaki E, Saxentoff E, Troman C, et al. Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance. Lancet. 2022. https:\/\/doi.org\/10.1016\/s0140-6736(22)01804-9.","journal-title":"Lancet"},{"key":"2296_CR16","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00103-013-1693-6","volume":"56","author":"C Poethko-M\u00fcller","year":"2013","unstructured":"Poethko-M\u00fcller C, Schmitz R. Vaccination coverage in German adults: results of the German health interview and examination survey for adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56:845\u201357. https:\/\/doi.org\/10.1007\/s00103-013-1693-6.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"2296_CR17","unstructured":"Robert-Koch-Institut. 2022 Impfquoten von Kinderschutzimpfungen in Deutschland. Epidemiologisches Bulletin 48\/2022."},{"key":"2296_CR18","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1007\/s12134-021-00929-8","volume":"23","author":"S Feinstein","year":"2022","unstructured":"Feinstein S, Poleacovschi C, Drake R, Winters LA. States and refugee integration: a comparative analysis of France, Germany, and Switzerland. J Int Migr Integr. 2022;23:2167\u201394. https:\/\/doi.org\/10.1007\/s12134-021-00929-8.","journal-title":"J Int Migr Integr"},{"key":"2296_CR19","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.2147\/rmhp.S375021","volume":"15","author":"E Cojocaru","year":"2022","unstructured":"Cojocaru E, Cojocaru C, Cojocaru E, Oancea CI. Health risks during ukrainian humanitarian crisis. Risk Manag Healthc Policy. 2022;15:1775\u201381. https:\/\/doi.org\/10.2147\/rmhp.S375021.","journal-title":"Risk Manag Healthc Policy"},{"key":"2296_CR20","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/eurpub\/ckac041","volume":"32","author":"F Stoeckel","year":"2022","unstructured":"Stoeckel F, Carter C, Lyons BA, Reifler J. The politics of vaccine hesitancy in Europe. Eur J Public Health. 2022;32:636\u201342. https:\/\/doi.org\/10.1093\/eurpub\/ckac041.","journal-title":"Eur J Public Health"},{"key":"2296_CR21","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1016\/j.vaccine.2022.05.022","volume":"40","author":"J Salmanton-Garc\u00eda","year":"2022","unstructured":"Salmanton-Garc\u00eda J, Stewart FA, Heringer S, Koniordou M, \u00c1lvarez-Barco E, Argyropoulos CD, et al. VACCELERATE volunteer registry: a European study participant database to facilitate clinical trial enrolment. Vaccine. 2022;40:4090\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2022.05.022. Accessed 5 May 2023","journal-title":"Vaccine"},{"key":"2296_CR22","unstructured":"Robert-Koch-Institut. Tasks and Aims. https:\/\/www.rki.de\/EN\/Content\/Institute\/institute_node.html."},{"key":"2296_CR23","unstructured":"Robert-Koch-Institut. KV-Impfsurveillance: Auswertung von Abrechnungsdaten der Kassen\u00e4rztlichen Vereinigungen. (2023). https:\/\/www.rki.de\/DE\/Content\/Infekt\/Impfen\/Impfstatus\/kv-impfsurveillance\/kvis_node.html#doc2391060bodyText2. Accessed 05 May 2023."},{"key":"2296_CR24","unstructured":"Robert-Koch-Institut. Schutzimpfung gegen Poliomyelitis: H\u00e4ufig gestellte Fragen und Antworten. (2022). https:\/\/www.rki.de\/SharedDocs\/FAQ\/Impfen\/Poliomyelitis\/FAQ-Liste_Poliomyelitis_Impfen.html. Accessed 02 May 2023."},{"key":"2296_CR25","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s00103-004-0952-y","volume":"47","author":"S Reiter","year":"2004","unstructured":"Reiter S. Ausgew\u00e4hlte Daten zum Impf- und Immunstatus in Deutschland. Bundesgesundheitsblatt - Gesundheitsforschung -Gesundheitsschutz. 2004;47:1144\u201350. https:\/\/doi.org\/10.1007\/s00103-004-0952-y.","journal-title":"Bundesgesundheitsblatt - Gesundheitsforschung -Gesundheitsschutz"},{"key":"2296_CR26","unstructured":"Robert-Koch-Institut. Archiv der STIKO-Empfehlungen. (2023). https:\/\/www.rki.de\/DE\/Content\/Kommissionen\/STIKO\/Empfehlungen\/Archiv\/seit_1972\/archiv_tab.html. Accessed 05 May 2023."},{"key":"2296_CR27","unstructured":"Bundesamt S. Bev\u00f6lkerung - Anzahl der Einwohner in den Bundesl\u00e4ndern in Deutschland am 31. Dezember 2021. (2022). https:\/\/de.statista.com\/statistik\/daten\/studie\/71085\/umfrage\/verteilung-der-einwohnerzahl-nach-bundeslaendern\/. Accessed 05 May 2023."},{"key":"2296_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4161\/hv.18444","volume":"8","author":"P Plans-Rubi\u00f3","year":"2012","unstructured":"Plans-Rubi\u00f3 P. Evaluation of the establishment of herd immunity in the population by means of serological surveys and vaccination coverage. Hum Vaccin Immunother. 2012;8:184\u20138. https:\/\/doi.org\/10.4161\/hv.18444.","journal-title":"Hum Vaccin Immunother"},{"key":"2296_CR29","unstructured":"European Centre for Disease Prevention and Control. Wild-type poliovirus 1 transmission in Israel \u2013 what is the risk to the EU\/EEA? Stockholm: ECDC. 2013. polio-risk-assessment-transmission-in-Israel.pdf (europa.eu). Accessed 05 May 2024."},{"key":"2296_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00253-1","author":"J Mercader-Barcel\u00f3","year":"2022","unstructured":"Mercader-Barcel\u00f3 J, Otu A, Townley TA, Adepoju P, Walley J, Okoibhole LO, et al. Rare recurrences of poliomyelitis in non-endemic countries after eradication: a call for global action. Lancet Microbe. 2022. https:\/\/doi.org\/10.1016\/S2666-5247(22)00253-1.","journal-title":"Lancet Microbe"},{"key":"2296_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2334-2-2","volume":"2","author":"S Diedrich","year":"2002","unstructured":"Diedrich S, Claus H, Schreier E. Immunity status against poliomyelitis in Germany: determination of cut-off values in International Units. BMC Infect Dis. 2002;2:2. https:\/\/doi.org\/10.1186\/1471-2334-2-2.","journal-title":"BMC Infect Dis"},{"key":"2296_CR32","doi-asserted-by":"publisher","first-page":"215013272095853","DOI":"10.1177\/2150132720958532","volume":"11","author":"A Applewhite","year":"2020","unstructured":"Applewhite A, Stancampiano FF, Harris DM, Manaois A, Dimuna J, Glenn J, et al. A retrospective analysis of gender-based difference in adherence to influenza vaccination during the 2018\u20132019 season. J Prim Care Community Health. 2020;11:2150132720958532. https:\/\/doi.org\/10.1177\/2150132720958532.","journal-title":"J Prim Care Community Health"},{"key":"2296_CR33","doi-asserted-by":"publisher","first-page":"e059944","DOI":"10.1136\/bmjopen-2021-059944","volume":"12","author":"JG Ray","year":"2022","unstructured":"Ray JG, Park AL. SARS-CoV-2 vaccination, ABO blood group and risk of COVID-19: population-based cohort study. BMJ Open. 2022;12:e059944. https:\/\/doi.org\/10.1136\/bmjopen-2021-059944.","journal-title":"BMJ Open"},{"key":"2296_CR34","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1353\/hpu.2014.0154","volume":"25","author":"S Matoff-Stepp","year":"2014","unstructured":"Matoff-Stepp S, Applebaum B, Pooler J, Kavanagh E. Women as health care decision-makers: implications for health care coverage in the United States. J Health Care Poor Underserved. 2014;25:1507\u201313. https:\/\/doi.org\/10.1353\/hpu.2014.0154.","journal-title":"J Health Care Poor Underserved"},{"key":"2296_CR35","unstructured":"Benedikt M, Tobias H. vacuna. (2019\u20132023). https:\/\/vacuna.io\/. Accessed 04 May 2023."}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02296-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-024-02296-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02296-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T14:51:50Z","timestamp":1722351110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-024-02296-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2296"],"URL":"https:\/\/doi.org\/10.1007\/s15010-024-02296-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3956278\/v1","asserted-by":"object"}]},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"14 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HJS has received consultancy or speaker honoraria from Pfizer, CSL Seqirus, Sanofi, Cologne University, Global Health Press, Minervax, VacciZONE and GOPA\/KfW. JAN has received speaker honoraria by Hikma. JSG has received speaker honoraria from Gilead and Pfizer. JS has received research grants by the Ministry of Education and Research (BMBF) and Basilea Pharmaceuticals Inc.; has received speaker honoraria by Pfizer Inc., Gilead, Hikma and AbbVie; has been a consultant to Gilead, Alvea Vax. and Micron Research. PWGM has received honoraria and\/or travel grants from Astrazeneza, Gilead Sciences, ViiV, Janssen and Pfizer. OAC reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Abbvie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, Pardes, Pfizer, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Abbvie, Al-Jazeera Pharmaceuticals, Astellas, Gilead, Grupo Biotoscana\/United Medical\/Knight, Hikma, MedScape, MedUpdate, Merck\/MSD, Mylan, Noscendo, Pfizer, Shionogi; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Janssen, MedPace, Paratek, PSI, Pulmocide, Shionogi, The Prime Meridian Group; A patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); Stocks from CoRe Consulting, and EasyRadiology. LMC, MZ and ZDP have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}